Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lipikar Baume AP+M + Lipikar Syndet is a complementary skincare regimen developed by La Roche-Posay (a brand of L'Oréal) specifically for the management of atopic eczema-prone, severely dry, and itchy skin. The regimen consists of two primary products: Lipikar Syndet AP+, a soap-free cream cleanser, and Lipikar Baume AP+M, a lipid-replenishing balm. These products are formulated with functional ingredients including Aqua Posae Filiformis (a postbiotic derived from thermal spring water), niacinamide, and shea butter. The regimen works by rebalancing the skin microbiome and restoring the epidermal moisture barrier. Clinical studies have demonstrated that daily use of this combination significantly reduces pruritus intensity, improves skin hydration, and enhances sleep quality and overall quality of life in patients ranging from newborns to adults. While marketed as cosmeceutical products rather than prescription pharmaceuticals, they are used as a therapeutic adjunct to standard atopic dermatitis treatments to prevent exacerbations and reduce relapse rates.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lipikar Baume AP+M + Lipikar Syndet.